These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 26329698)

  • 1. Targeting molecular resistance in castration-resistant prostate cancer.
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    BMC Med; 2015 Sep; 13():206. PubMed ID: 26329698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of chemotherapy in the treatment of castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2016 Jan; 74(1):143-8. PubMed ID: 26793895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
    Galletti G; Leach BI; Lam L; Tagawa ST
    Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein.
    Zhang Y; Wei W; Li C; Yan S; Wang S; Xiao S; He C; Li J; Qi Z; Li B; Yang K; Li C
    Cell Death Dis; 2022 Dec; 13(12):1034. PubMed ID: 36509750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
    Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
    Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
    Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy for CRPC].
    Ozono S; Furuse H
    Nihon Rinsho; 2014 Dec; 72(12):2170-3. PubMed ID: 25518353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M; Eto M
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Therapeutic Resistance in Prostate Cancer.
    Nakazawa M; Paller C; Kyprianou N
    Curr Oncol Rep; 2017 Feb; 19(2):13. PubMed ID: 28229393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing of agents for castration-resistant prostate cancer.
    Hurwitz M; Petrylak DP
    Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.